EGFR and osteosarcoma: In this paper, we also found that the combinative treatment with COX-2 inhibitor celecoxib and EGFR inhibitor ZD6474 presented a synergistic/additive antitumor effect on osteosarcoma in vivo and in vitro (Figure 5 and Figure 6).